KRIYA.497

KRIYA.497 is an investigational gene therapy being developed by Kriya Therapeutics for the treatment of steatotic liver disease (SLD). The therapy is designed to deliver a functional DNA sequence directly to target liver cells to enable the durable expression of a therapeutic protein following a single administration. By leveraging gene transfer technology, KRIYA.497 aims to address the underlying metabolic dysregulation associated with SLD, which encompasses conditions such as nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). The program is part of Kriya's metabolic disease pipeline and utilizes their proprietary platform for efficient gene delivery and expression.